Clinical study of irinotecan combined with 5-Fu/CF in the treatment of patients with advanced colorectal cancer

VernacularTitle:FOLFIRI方案二线治疗晚期大肠癌临床疗效观察
Author: Qing REN ; Jingwu WU ; Ruihua XIONG ; Xin ZHOU
Publication Type:Journal Article
Keywords: Intestinal neoplasms; Drug therapy,combination; Therapy
From: Cancer Research and Clinic 2011;23(1):28-30
CountryChina
Language:Chinese
Abstract: Objective To evaluate the anti-tumor activity and toxicity of FOLFIRI regimen in the treatment of patients with advanced colorectal cancer. Methods 22 patients with advanced colorectal cancer used Irinotecan combined with 5-Fu/CF regimen to chemotherapy. Regimen: CPT-11 150 mg/m2 iv drip d1, CF 200 mg/m2 iv drip 2 h d1, 2; 5-Fu 400 mg/m2 iv drip d1, 2; 5-Fu 600 mg/m2 iv drip 22 h d1, 2. It is repeated every 2 weeks, two times a course. Efficiency and toxicity was evaluated after 4-6 cycles. Results Forty four patients were evaluated the efficiency. Two patients achieved CR, 16 PR, response rate was 40.9 %; MST was 11.3 months. TTP was 6.5 months. The main toxicity was cholinergic syndrome and delayed diarrhea,myelosuppression. There were no deaths during treatment. Conclusion The effectiveness of FOLFIRI regimen was higher and side effects was minor in advanced colorectal cancer. It should be further used and studied.